A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body

Healthy Subjects Clinical Trial

Official title:

An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Pracinostat in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03495934
• Other study ID #: PRAN-17-17
• Status: Completed
• Phase: Phase 1
• Start date: February 8, 2018
• Est. completion date: February 28, 2018

Study information

• Verified date: August 2019
• Source: Helsinn Healthcare SA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current study is designed to generate data for the investigation of absorption, distribution, metabolism and elimination (ADME) processes of pracinostat in humans, as well as generating samples for metabolite profiling and structural identification. The mass balance recovery of pracinostat following administration of [14C]-pracinostat will be assessed, as well as metabolite profiling and identification of pracinostat in healthy male subjects. In addition, this study will provide further PK and safety data in healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: February 28, 2018
• Est. primary completion date: February 28, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy males

2. Age 40 to 65 years, inclusive

3. Body mass index of 18.0 to 35.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator

4. Must be willing and able to communicate and participate in the whole study

5. Must have regular bowel movements (i.e., average stool production of =1 and =3 stools per day)

6. Subject is considered healthy on the basis of medical history, physical examination, triplicate electrocardiogram (ECG), vital signs and clinical laboratory assessments.

7. Provision of written informed consent to participate as shown by a signature on the volunteer consent form.

8. Male subjects must not be seeking to father a child in the next 6 months (covering 2 cycles of spermatogenesis) and must agree to use an adequate method of contraception -

Exclusion Criteria:

1. Subjects who have received any IMP in a clinical research study within the previous 3 months

2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee

3. Subjects with pregnant partners

4. Subjects who have previously been enrolled in this study

5. Subjects who have been enrolled in an absorption, distribution, metabolism and elimination (ADME) study in the last 12 months

6. History of any drug or alcohol abuse in the past 2 years

7. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit; 1.5 to 2 units = 125 mL glass of wine, depending on type)

8. Current smokers and those who have smoked within the last 12 months. A positive urine cotinine test at screening and admission

9. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months

10. Radiation exposure, excluding background radiation but including significant medical exposures, or other trial related exposures, in the 12 months preceding participation in the trial, or radiation exposure exceeding 10 mSv in the 5 years preceding participation in the trial, inclusive of the 5 mSv exposure resulting from participation in this study. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study. Significance of a medical exposure will be determined by the investigator.

11. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening

12. Clinically significant abnormal biochemistry, haematology, coagulation or urinalysis at screening as judged by the investigator

13. Positive drugs of abuse test result

14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results

15. Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <80 mL/min using the Cockcroft-Gault equation

16. Evidence of abnormal liver function at screening; alanine/aspartate aminotransferase or alkaline phosphatase > 1.5 × the upper limit of normal (ULN) or total bilirubin > 2 × ULN

17. White blood cells count (including differential), platelet count or red blood cell count below the lower limit of normal at screening

18. QT interval corrected for heart rate using Fridericia's formula (QTcF) > 450 msec (using mean of triplicate ECG)

19. History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal (GI) disease, or psychiatric disorder, as judged by the investigator

20. Subjects with a history of cholecystectomy or gall stones

21. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients

22. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active

23. Donation or loss of greater than 400 mL of blood within the previous 3 months

24. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor.

25. Subjects who have used any medication, foods or lifestyle products that induces cytochrome P450 (CYP)-1A2, -2C8 or -3A4 in the past 28 days

26. Any other reason why the investigator believes participation may not be in the best interests of the potential participant -

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• pracinostat
[14C]-pracinostat

Locations

Country	Name	City	State
United Kingdom	Quotient Science	Ruddington

Sponsors (2)

Lead Sponsor	Collaborator
Helsinn Healthcare SA	Quotient Sciences

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mass balance recovery	urine and faeces will becollected at different time points and the radioactivity will be measured. The recovery will be expressed as percentage of radioactivity administrated	up to 12 days
Primary	Area Under the Curve (AUC)	blood and plasma samples will be collected and the radioactivity measured to determine the Area under the concentration-time curve	up to 8 days
Primary	Maximum concentration (Cmax)	blood and plasma samples will be collected and the radioactivity measured to determine the max concentration in concentration-time curve	up to 8 days
Primary	clearance (CL/F)	systemic clearance after extravascular administration	up to 8 days
Primary	Volume of distribution (Vd/F)	volume of distribution after extravascular administration	up to measurable concentration
Primary	terminal half life (t1/2)	blood and plasma samples will be collected and the radioactivity measured to determine the terminal half life of the concentration-time curve	up to 8 days